BCR-ABL1 Quantitative PCR in Chronic Myelogenous Leukemia
Description: Dan Jones, MD, PhD, discusses the BCR-ABL1 kinase domain and imatinib resistance in chronic myelogenous leukemia, and the clinical value of the international scale and trending reports for managing patients with CML.
Learning objectives - at the conclusion of this program participants will be able to:
o Communicate the role of BCR-ABL1 PCR in guiding treatment and detecting imatinib resistance
o Describe the new report format for incorporates normalization to the International Scale (IS)
o Discuss the usefulness of longitudinal trending reports to detect primary resistance and emerging secondary resistance
o Describe how and when to test patients for imatinib resistance